» Articles » PMID: 17512133

Ultrasound-guided Transrectal Implantation of Gold Markers for Prostate Localization During External Beam Radiotherapy: Complication Rate and Risk Factors

Overview
Specialties Oncology
Radiology
Date 2007 May 22
PMID 17512133
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To report the complication rate and risk factors of transrectally implanted gold markers, used for prostate position verification and correction procedures.

Methods And Materials: In 209 consecutive men with localized prostate cancer, four gold markers (1 x 7 mm) were inserted under ultrasound guidance in an outpatient setting, and the toxicity was analyzed. All patients received a questionnaire regarding complications after marker implantation. The complications and risk factors were further evaluated by reviewing the medical charts.

Results: Of the 209 men, 13 (6.2%) had a moderate complication, consisting of pain and fever that resolved after treatment with oral medication. In 1.9% of the men, minor voiding complaints were observed. Other minor transient complications, defined as hematuria lasting >3 days, hematospermia, and rectal bleeding, occurred in 3.8%, 18.5%, and 9.1% of the patients, respectively. These complications were seen more often in patients with advanced tumor stage, younger age, and shorter duration of hormonal therapy.

Conclusion: Transrectal gold marker implantation for high-precision prostate radiotherapy is a safe and well-tolerated procedure.

Citing Articles

Transperineal versus transrectal prostate fiducial insertion in radiation treatment of prostate cancer: a systematic review and meta-analysis.

Hong S, Bae S, Hwang J, Lee E Ultrasonography. 2024; 43(4):229-237.

PMID: 38898635 PMC: 11222131. DOI: 10.14366/usg.23229.


CT-guided Transgluteal Prostate Fiducial Marker Insertion for Localized Radiation Therapy.

Khanmohammadi S, Golzarian J, Akhlaghpoor S Cardiovasc Intervent Radiol. 2023; 46(10):1409-1413.

PMID: 37640950 DOI: 10.1007/s00270-023-03539-2.


Intra-prostatic gold fiducial marker insertion for image-guided radiotherapy (IGRT): five-year experience on 795 patients.

Mahdavi A, Mofid B, Taghizadeh-Hesary F BMC Med Imaging. 2023; 23(1):79.

PMID: 37308834 PMC: 10262562. DOI: 10.1186/s12880-023-01036-z.


Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study.

Bjoreland U, Notstam K, Fransson P, Soderkvist K, Beckman L, Jonsson J Radiat Oncol. 2023; 18(1):1.

PMID: 36593460 PMC: 9809044. DOI: 10.1186/s13014-022-02197-x.


Cost-Effectiveness of the Use of Gold Anchor™ Markers in Prostate Cancer.

Lundqvist M, Levin L Cureus. 2020; 12(10):e11229.

PMID: 33269157 PMC: 7706143. DOI: 10.7759/cureus.11229.